Over the past five years, regulatory chaos in the antibiotics field has created a sort of solidarity between biotechs that would otherwise be competitors.
Trius Therapeutics Inc. hit all primary and secondary endpoints in its first Phase III trial of antibiotic tedizolid (formerly torezolid), yet investors rewarded the San Diego biotech by pushing its shares down 12 percent.
For more than 20 years, erythropoiesis-stimulating agents (ESAs) have dominated the anemia field. But this month's advisory committee win by Affymax Inc.'s peginesatide, as well as new data coming out of the American Society of Nephrology's Kidney Week and the American Society of Hematology's annual meeting, indicate big changes are afoot – changes that impact competitors not only in the ESA space but in the iron-replacement space as well.
While all you biotechs out there scramble to meet your end-of-year milestones, BioWorld would like to announce a little milestone of our own. That’s right, this is our fifth annual biotech holiday gift guide. To celebrate five years of excellent gift recommendations for every biotechie on your list – be they scientist, fashionista, bibliophile, new parent, Wall Street exec, traveler, or anyone else – we’re bringing you a Top 10 list of our staff’s all-time favorites. So without further ado: 10. Ever wanted to wash yourself with E. Coli or S. Enteritidis? Now you can, with Petri Dish Soaps, a...
Onyx Pharmaceuticals Inc.'s plan to seek accelerated approval for multiple myeloma drug carfilzomib based on data from an open-label, single-arm Phase IIb trial was always risky – but it might have gotten a bit riskier over the weekend.
Four months ago, Coronado Biosciences Inc. embarked on a route to going public not often seen in the biotech industry: the Form 10 pathway. (See BioWorld Today, July 20, 2011.)
SAN DIEGO – Geron Inc.'s exit from the embryonic stem cell field last month shocked many in the biotech industry – but not the regenerative medicine experts attending the recent 2011 Stem Cell Meeting on the Mesa.
Hematologic cancers always grab the spotlight at the American Society of Hematology (ASH) annual meeting, which kicked off this weekend, but Pharmacyclics Inc. got a head start last week by announcing a $975 million deal with Janssen Biotech Inc. for Phase II hematologic cancer drug PCI-32765.
Affymax Inc. scored a big win on Wednesday when the FDA's Oncologic Drugs Advisory Committee voted 15-to-1 in favor of peginesatide for dialysis patients with anemia due to chronic kidney disease (CKD).
Stem cell therapies may be relatively early stage, but that hasn’t stopped their developers from giving some serious thought to late stage issues like reimbursement and health economics. At the recent 2011 Stem Cell Meeting on the Mesa, panelists debated how careful consideration of such issues might help them avoid following in the footsteps of Dendreon Corp. First hailed as a front-runner of the cell therapy field for getting FDA approval of prostate cancer vaccine Provenge (sipuleucel-T), Dendreon has since become the red-headed stepchild of many analysts and investors due to its failure to gain commercial traction for the product....
